HPV Vaccination Recommendation

HPV Vaccine Recommendations & Current
Issues

Gregory Zimet, PhD

Professor, Department of Pediatrics
Section of Adolescent Medicine
Indiana University School of Medicine

Disclosures

 Investigator on HPV-related research grants funded by
Merck’s Investigator-Initiated Science Program

Outline

 Current status of HPV vaccine
recommendations
 HPV vaccine safety
 HPV vaccination rates
 Summary & recommendations

CURRENT STATUS OF HPV
VACCINE RECOMMENDATIONS

HPV Vaccine Licensure: FDA

 Quadrivalent Vaccine
 Females 9-26 years old (licensed in 2006)
 Males 9-26 years old (licensed in 2009)
 Bivalent Vaccine
 Females 9-26 years old (licensed in 2009)

ACIP HPV Vaccine
Recommendations for
FEMALES

 Quadrivalent (licensed 2006):
 For prevention of vaginal, vulvar, and cervical precancers and
cancers, genital warts, and anal precancers (AIN 2/3)

 Bivalent (licensed 2009):
 For prevention of vaginal, vulvar, and cervical precancers and
cancers

 Both vaccines:
 Routine administration for 11-12 year old girls
 Administration for 9-10 year old girls at provider’s/parental
discretion
 Administration for 13-26 year old females not previously
vaccinated

ACIP HPV Vaccine
Recommendations for
MALES

 Quadrivalent vaccine only:
 2009 – permissive recommendation; 2011 – routine
recommendation
 For prevention of genital warts & anal precancers (AIN 2/3)
 Routine administration for 11-12 year old boys
 Administration for 9-10 year old boys at provider’s/parental
discretion
 Administration for 13-21 year old males not previously
vaccinated
 Males 22-26 may get vaccinated by not strongly recommended
 Men who have sex with men (MSM) should be immunized up to

Other Recommendations

 Previous sexual activity not a contraindication
 No testing for prior HPV exposure necessary
 HIV-infected males and females 9-26 should get
3-dose quadrivalent vaccine series
 HPV vaccines can be co-administered during
same visit with other recommended vaccines
(e.g., MCV4; Tdap)

Other Recommendations

 Though no known danger exists, HPV vaccine is
not recommended for pregnant women
 Cervical cancer screening recommendations
should be followed regardless of vaccination
status
 No evidence for prevention of penile
cancers, oropharyngeal cancers, or RRP

HPV Vaccines are Safe

 Safety continues to be closely monitored by
several different systems*
 VAERS data to date show no concerns about
safety**
 Study based on over 600,000 doses of vaccine
found no increased risk for***:
 Stroke
 Seizures * Markowitz et al. Vaccine 2010.
** Slade et al. JAMA 2009.
 Allergic reactions *** Gee et al. Vaccine 2011.
 Many other conditions


 Examination of multiple studies that compared
vaccine recipients to placebo recipients*:
 About 22,000 persons in each of the 2 groups
 Severe adverse events examined included: adverse
pregnancy outcomes, immune system
problems, heart problems, and nervous system
problems
 Severe adverse events occurred rarely in both
groups
 NO DIFFERENCE FOUND *Lu et al. BMC Infect Dis 2011.
BETWEEN THE
VACCINE GROUP AND THE CONTROL GROUP


 All of the evidence to date indicates that HPV
vaccination is much safer for children &
adolescents than:
 Playing soccer
 Taking Tylenol (acetaminophen)
 Riding in or driving a car
 Mowing the lawn

HOT TOPIC #2: HPV VACCINATION
RATES

Indiana: Cervical cancer
summary
 Hispanic women have higher incidence of
invasive cervical cancer compared to other
women
 Black women have higher cervical cancer
incidence and mortality than white women
 Indiana and national rates of cervical cancer
incidence and mortality are roughly equivalent
 Lake county has a cervical cancer death rate
that is nearly twice the national rate
From: Swanson, Weathers, Rakowski. “Cancer Disparities in Indiana:
An Epidemiologic Profile”. IUSCC, IU Public Health, ACS.

From: Swanson, Weathers, Rakowski. “Cancer
Disparities in Indiana: An Epidemiologic Profile”.
IUSCC, IU Public Health, ACS.

2010 HPV Vaccination Rates for 13-17
year old girls*
80%

70%

60%
73%
50%
58%
40% 49% 1st Dose
3 Doses
30%
34% 37%
20% 29%

10%

0%
U.S. Indiana Rhode Is.

*CDC MMWR 2011.

2009 Indiana HPV Vaccination Rates
for 13-17 year old girls*
60% 1st Dose

50%

40%
52%
30% 37%

31%
20%

10%

0%
Indiana Marion Cty Lake Cty

*CDC MMWR 2010.

2010 Vaccination Rates: Other
findings*
 Indiana is 4th from the bottom in HPV
vaccination
 Male vaccination: Nationally,1%-2% received 1
or more doses
 Meningococcal vaccine
 63% nationally
 71% Indiana
 2007-09 U. Mich. Health Systems
 18% of 19-26 yr old women vaccinated*
*CDC MMWR 2011
 2008 North Carolina Survey Dempsey et al. Vaccine 2011
Reiter et al. Sex Trans Dis 2010
 19% of 10-12 yr old girls vaccinated*

Contrasts: Race & Hispanic Ethnicity*

80%

70%
75%
60%
65%
50%
56% White, non-
56%
40% Hisp
46% 49% Black, non-
30% His.

20%

10%

0%
1st Dose Series Completion
*CDC MMWR 2011.

Contrasts: Poverty Status*

80%

70%

60% 73%

50% Poverty Level:
57%
At or Above
40% 52%
48%
Below
30%

20%

10%

0%
1st Dose Series Completion
*CDC MMWR 2011.

Summary: The good, the bad, and the
ugly
 The good
 HPV vaccines are very effective
 HPV vaccines are very safe
 All 11-12 year olds should be receiving HPV vaccine
 The bad
 The U.S. in general has not done well with HPV
vaccination, particularly with targeted age group
 Indiana is 4th from the bottom of all states in HPV vaccination
rates for 13-17 year old girls
 The ugly
 Completion rates for non-Hispanic Blacks, Hispanics, and those
who fall below the poverty line are unacceptably low

Recommendations

 Develop and test new and creative strategies to
increase acceptance of vaccine and reduce
disparities in series completion
 Focus on Lake County
 Look to Rhode
Island, Massachusetts, Washington State, and
South Dakota as examples of fairly successful
HPV vaccination programs

HPV Vaccination Recommendation

More Related Content

What's hot (20)

Similar to HPV Vaccination Recommendation (20)

More from Nikki Davis (6)

Recently uploaded (20)

HPV Vaccination Recommendation